Solid Biosciences

#TeamSolid is proud to welcome our Fall Co-Op cohort! These talented individuals have joined teams across the company. Welcome aboard:
 Tala Bongalon – Bioanalytical Sciences Co-Op
 Jessica Carmody – R&D Viral Transduction Co-Op
 Nirali Chavda – Analytical Development Co-Op
 Shriya Gadichanda – Human Resources Co-Op
 Olivia Heynes – R&D Gene Therapy Co-Op
 Vamshi Krishna Korutla – Process Development Co-Op Joshua Perez – R&D Discovery Biology Co-Op
 Sloane Roy – Downstream Process Development Co-Op
 We’re excited to have you on board and can’t wait to see the impact you’ll make as part of our mission to improve the lives of patients with rare diseases. #TogetherWeAreSolid #HappyNationalInternDay

Solid Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SGT-501, our novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia (#CPVT).     The designation enables more frequent interactions with the FDA and may also make SGT-501 eligible for priority review, helping to potentially accelerate the development and availability of new treatment options for individuals living with CPVT.    Read the full release: https://lnkd.in/eczUn-4x   #VentricularTachycardia #GeneTherapy #SolidBiosciences #RareDiseaseResearch 

Solid is proud to sponsor Team Joseph's What Now? Virtual Conference, happening July 16-17 — the only conference created by and for older adolescents and adults living with Duchenne muscular dystrophy. This free, fully virtual event will explore the real questions and lived experiences of adulthood with Duchenne — from purpose and autonomy to careers, relationships, mental health, finances, friendship, travel, and more. We’re especially honored to take part in the Community Campfire, a space for connection and stories of the Duchenne community. Thank you to Team Joseph for leading this effort and making space for voices that need to be heard. Learn more here: https://lnkd.in/ewRc46SD  #DuchenneCommunity #DuchenneMuscularDystrophy #TeamJoseph #RareDiseaseCommunity  

We are honored to share the story of the Berko family who tragically lost a child to CPVT, a rare heart condition – one they only learned about after their second child narrowly survived a sudden cardiac arrest event.    CPVT, catecholaminergic polymorphic ventricular tachycardia, is a life-threatening, genetic heart rhythm condition that often affects children in its most severe form.     Solid is committed to advancing SGT-501, a potential first-in-class gene therapy to treat CPVT, to the clinic in the fourth quarter of 2025 – aiming to improve the lives of people living with this condition.     #CPVT #VentricularTachycardia #GeneTherapy #SolidBiosciences #RareDiseaseResearch

Solid Biosciences is pleased to share the approval of our Investigational New Drug application by the FDA and Clinical Trial Application by Health Canada for SGT-501, a novel gene therapy approach for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT).     CPVT is a rare, life-threatening, genetic arrhythmogenic disease with no approved therapy, and SGT-501 has potential as a first-in-class therapy to address the underlying causes of CPVT.  We are grateful for the work from our partners at the IRCCS Maugeri Pavia, Italy, who pioneered the AAV-CASQ2 gene therapy approach utilized by SGT-501. We look forward to initiating a Phase 1b clinical trial of SGT-501 in the fourth quarter of 2025 and are proud to trailblaze new treatments for rare diseases. Read the full release: https://lnkd.in/eqChC-m7   #CPVT #VentricularTachycardia #GeneTherapy #SolidBiosciences #RareDiseaseResearch

We had an amazing time participating in Friedreich's Ataxia Research Alliance (FARA)'s rideATAXIA Hometown Boston event at the end of June! So many riders, families and advocates came together for the singular purpose of supporting the Friedreich's Ataxia (FA) community.   It was a privilege to hear from several speakers living with FA; their courage, resiliency, humor, and hope inspired us all – providing excellent motivation for the ride. A huge thanks to the FARA team for organizing a wonderful event and for the opportunity to raise awareness of FA.   #FriedreichsAtaxia #rideATAXIA #FAresearch #RareDisease

#TeamSolid proudly participated in the Boston Athletic Association's 10K presented by Brigham and Women's Hospital!   We were honored to run on behalf of the Brigham’s Cardiovascular Genetics Fund – an important cause that aligns with our mission of advancing science for individuals and families impacted by cardiac genetic diseases.   Congratulations to all the runners and thank you to the Brigham and the B.A.A. for hosting an incredible event.    #BAA10K #BrighamandWomensHospital #CardiacHealth

At Solid, our Spring Co-Ops have gone beyond the basics – gaining hands-on experience, growing professionally, and contributing to our mission. Hear from our Co-Ops about what made their time at Solid so impactful: Rohith Karunakaran, Associate Scientist, Immunology Co-Op:
“More than the lab work, I saw how teamwork, curiosity, and a shared goal to help patients can truly drive meaningful progress. Thank you to the amazing team at Solid for making this experience so valuable and inspiring!” Jaini Patel, Discovery Biology Co-op:
“Exploring techniques like antibody validation and flow cytometry was exciting, but what stood out most were the people. The support from my team helped build my confidence in the lab and made this Co-Op truly special.” Ved Vyas, R&D, Viral Transduction Co-op:
“Solid gave me a front-row seat to patient-centric innovation and the gene therapy pipeline, from preclinical to clinical. I’ll carry this experience with me as I continue growing in my career.” Ben Tasker, R&D, Vector Biology Co-op:
“My biggest takeaways? Teamwork, communication, and consistency. The support from my team showed me the power of collaboration, and I’ve seen firsthand how practice really does lead to progress.” Kudos to all our Co-Ops for your hard work and dedication! #TogetherWeAreSolid #CoOpSpotlight #RareDiseaseResearch #BiotechCareers

Thank you, #PPMD2025! We were grateful for the opportunity to connect with the Duchenne community in Las Vegas and share more about SGT-003, our next-generation, investigational gene therapy for Duchenne muscular dystrophy. We appreciated the chance to listen, learn, and engage – and we look forward to continuing to provide updates on INSPIRE DUCHENNE clinical program.

Solid Biosciences is heading to Parent Project Muscular Dystrophy’s 2025 Annual Conference in Las Vegas!   Learn more about SGT-003, our next-generation, investigational gene therapy for Duchenne muscular dystrophy during the session, “Exploring the Landscape of Gene Therapy,” on Thursday, June 19 from 3:30-5:00 PM PT. Want to continue the conversation? Stop by booth #7 in the exhibit hall - our team would love to connect. Learn more about the event here: https://lnkd.in/er8sqyzM #PPMD2025 #GeneTherapy #DuchenneMuscularDystrophy